SCHEMBL14645442

SCHEMBL14645442

COC(=O)Cc1ccsc1-c1ccc(-c2sc(Br)cc2CC(=O)OC)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.46
TP53 P04637 3/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 4/20 0.40
RXFP1 Q9HBX9 2/20 0.36
PTGS1 P23219 1/20 0.34
KAT2B Q92831 1/20 0.34
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 3/20 0.34
GLA P06280 2/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 4/20 0.33
MEN1 O00255 3/20 0.33
HTT P42858 2/20 0.33
ACLY P53396 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14646123 0.95 KMT2A (0.45) KMT2ATP53ALOX15MAPK1MAPT
SCHEMBL15695238 0.95 MAPT (0.41) KMT2ATP53ALOX15MAPK1MAPT
SCHEMBL14646017 0.91 TP53 (0.46) KMT2ATP53ALOX15MAPK1MAPT
SCHEMBL14645539 0.91 KMT2A (0.40) KMT2ATP53ALOX15MAPK1MAPT
SCHEMBL14646005 0.91 MAPT (0.46) KMT2ATP53MAPTRXFP1ALDH1A1
SCHEMBL15695235 0.87 MAPT (0.46) KMT2ATP53MAPTRXFP1ALDH1A1
SCHEMBL14645421 0.86 KMT2A (0.54) KMT2ATP53ALOX15MAPK1MAPT
SCHEMBL14645340 0.86 KMT2A (0.36) KMT2ATP53ALOX15MAPK1MAPT
SCHEMBL15695234 0.82 KMT2A (0.50) KMT2ATP53ALOX15MAPK1MAPT
SCHEMBL14645332 0.82 HSP90AB1 (0.42) KMT2ATP53MAPTKAT2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 EP claimed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 WO claimed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 KMT2A 4329/4885TP53 165/4885ALOX15 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.